Pipeline
Pipeline
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dipasol |
Wound Care |
None invasive composition stimulating the division, migration, and differentiation of autologous stem cells. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemma |
Hemostatic Device |
In studies, Gemma has shown to stop bleeding 15 times faster than other commercially available hemostats. Gemma is a unique biodegradable composition that has minimal local and no systemic side effects. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
F-RNA |
Antisense oligonucleotides |
Fragmentation of tRNA (fRNA) further modifying the structure of oligomeric fragments so that the fragments acquire not only the classical properties of antisense oligonucleotides, but also acquire opposite charges. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-025 |
MDR bacteria potentiator |
Novel composition to restore MDR bacterial sensitivity to old & new generation antibiotics. |
|
||||||||||
|
NGL-022 |
Nephroprotector (Polymyxin nephrotoxicity) |
Novel composition protecting kidneys Polymyxin nephrotoxicity. |
|
||||||||||
|
NGL-028 |
Novel antimicrobial |
The self-organizing superstructure of modified polyphenols, decreases the chance for (preventing) bacterial resistance. |
|
||||||||||
|
NGL-050 |
Suppression TB reactivation |
Composition stimulating completion of macrophage phagocytosis in granulomas and prevent TB reactivation. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-030 |
Modified Probiotics |
The novel approach to shorten the time of probiotics onset (bacillus coagulans) from 3-4 days to 2-3 hours. Thereby exponentially improving probiotic efficacy. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-040 |
Chronic Fatigue Syndrome |
The composition based on the activation of telomerase somatic cells, improving their viability leading to increased energy levels. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-070 |
Oral insulin |
The novel composition of modified Insulin for oral use. |
|
||||||||||
Publications
Influence of non-metabolic microbial growth promotors on the sensitivity to antimicrobials
The control over multi-resistant nosocomial strains of microorganisms has been becoming increasingly urgent in recent years.
Creation of new medical drugs based on Triz and computer mathematical modeling
The article provides an overview of the current state of the use of TRIZ in the pharmaceutical industry and our R&D efforts in that area
Accumulation activators and their influence on multi-drug resistance microorganisms
Multi-drug resistant strains
have arisen over the years
due to over use of antibiotics in hospitals and in the veterinary space.
Pharmacological efficacy of a synergistic composition based on activators of cAMP accumulation as a wound healing agent
Wound-healing dipyridamole- and papaverine-based aerosols (D1/D2) are promising drugs that can accelerate wound healing in wound processes of various origins.